Detalhe da pesquisa
1.
Assessing the rate of non-linkage to care and identifying barriers in individuals living with hepatitis B. Results of the LINK-B study.
Liver Int
; 44(3): 706-714, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111084
2.
Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis.
Liver Int
; 43(12): 2611-2614, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916574
3.
Securing wider EU commitment to the elimination of hepatitis C virus.
Liver Int
; 43(2): 276-291, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36196744
4.
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
Gastroenterol Hepatol
; 46(10): 764-773, 2023 Dec.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36731726
5.
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
Clin Gastroenterol Hepatol
; 20(2): 438-446, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493697
6.
Etiologies and Features of Acute Viral Hepatitis in Spain.
Clin Gastroenterol Hepatol
; 19(5): 1030-1037, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663522
7.
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Liver Int
; 41 Suppl 1: 9-14, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34155802
8.
Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution.
Transpl Int
; 34(12): 2494-2506, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626501
9.
The Screening Guidelines for Hepatitis C Virus Infection as a milestone in the path towards hepatitis C virus elimination.
Rev Esp Enferm Dig
; 113(2): 156, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33508945
10.
Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
Semin Liver Dis
; 40(1): 49-60, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31805583
11.
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
J Hepatol
; 73(5): 1037-1045, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32553667
12.
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
J Hepatol
; 72(6): 1088-1096, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31981727
13.
Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?
J Viral Hepat
; 27(7): 747-753, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32106351
14.
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
Liver Int
; 40 Suppl 1: 15-21, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32077604
15.
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.
Liver Int
; 40(8): 1906-1916, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32329119
16.
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.
Rev Esp Enferm Dig
; 112(10): 778-783, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954777
17.
Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). / Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020).
Gastroenterol Hepatol
; 43(9): 559-587, 2020 Nov.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-32778356
18.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol
; 70(5): 1008-1015, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982526
19.
Sofosbuvir/velpatasvir for 12â¯weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
J Hepatol
; 71(4): 660-665, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31195062
20.
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
J Hepatol
; 71(4): 666-672, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31203153